Royalty Pharma (RPRX) – Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Royalty Pharma (NASDAQ: RPRX) in the last few weeks:

• 8/22/2026 – Royalty Pharma was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 8/12/2026 – Royalty Pharma had its “buy (b-)” rating reaffirmed by Weiss Ratings.
• 8/8/2026 – Royalty Pharma was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 8/7/2026 – Royalty Pharma had its price target raised by JPMorgan Chase & Co. from $58.00 to $62.00. They now have an “overweight” rating on the stock.
• 8/6/2026 – Royalty Pharma had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $66.00 price target on the stock.
• 8/6/2026 – Royalty Pharma had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $65.00 price target on the stock.
• 8/5/2026 – Royalty Pharma had its “buy” rating reaffirmed by Bank of America Corporation.
• 7/13/2026 – Royalty Pharma had its price target raised by TD Cowen from $50.00 to $65.00. They now have a “buy” rating on the stock.

Royalty Pharma Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a dividend of $0.235 per share. This represents a $0.94 annualized dividend and a dividend yield of 1.5%. The ex-dividend date of this dividend is Friday, August 14th. Royalty Pharma’s dividend payout ratio is currently 64.83%.

Insider Activity

In related news, EVP Marshall Urist sold 9,099 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $55.88, for a total transaction of $508,452.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 150,000 shares of Royalty Pharma stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $54.40, for a total value of $8,160,000.00. Following the completion of the sale, the executive vice president directly owned 559,399 shares in the company, valued at approximately $30,431,305.60. This represents a 21.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 398,197 shares of company stock valued at $22,513,280 over the last ninety days. 18.84% of the stock is owned by insiders.

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.